For roughly two years — from October 2022 to October 2024 — compounded tirzepatide was legally produced in large volumes under FDA shortage rules, and it reached hundreds of thousands of patients at a fraction of Zepbound's list price. Then the FDA declared the shortage resolved, litigation followed, and the compounding landscape has been reshaping itself ever since. This article is an honest, 2026-current comparison of Zepbound and compounded tirzepatide on formulation, concentration, cost, legal status, and quality control.
Key Takeaways
- Zepbound is Eli Lilly's FDA-approved brand of tirzepatide for obesity, delivered in pre-filled pens at 2.5, 5, 7.5, 10, 12.5, and 15 mg strengths.
- Compounded tirzepatide is pharmacy-made under section 503A (small compounding pharmacies) or 503B (outsourcing facilities), typically as a multi-dose vial requiring user drawing.
- The FDA tirzepatide shortage was declared in October 2022 and resolved in October 2024, which triggered restrictions on bulk compounding.
- Zepbound list price is roughly $1,000–$1,100 per month; compounded tirzepatide typically ran $300–$500 per month during the shortage window.
- Formulation differences are real — some compounded versions added vitamin B12 or lipotropic agents that have no SURMOUNT-trial data.
- By 2026, large compounders have mostly exited, though limited patient-specific 503A compounding may still occur under narrow conditions.
What Zepbound actually is
Zepbound is Eli Lilly's brand name for tirzepatide, FDA-approved for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. It is the same molecule as Mounjaro — Lilly's earlier brand approved for type 2 diabetes — but marketed and labelled for obesity. It is delivered as a single-dose pre-filled pen in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg, each 0.5 mL fixed-dose cartridge.
Because Zepbound is pre-filled, the user does not reconstitute, draw, or calculate concentrations. One pen = one dose. Lilly also launched a vial-based self-pay option (LillyDirect) in 2024 at lower prices for cash-pay patients.
What compounded tirzepatide actually was
Compounded tirzepatide is pharmacy-made tirzepatide, produced by either a 503A traditional compounding pharmacy (requires a patient-specific prescription, cannot be mass-produced) or a 503B outsourcing facility (can produce bulk, must meet stricter quality standards). During the FDA-declared shortage from October 2022 through October 2024, both pathways were used, and compounded tirzepatide reached a very large patient population through online weight-loss clinics.
Delivery was almost always a multi-dose vial that the patient reconstituted or that arrived pre-mixed at a stated concentration. Some pharmacies added accessory ingredients — notably vitamin B12 or lipotropic agents like methionine, inositol, and choline — which were not tested in SURMOUNT trials and have no established benefit for weight loss on top of tirzepatide.
Head-to-head comparison
| Attribute | Zepbound (FDA-approved) | Compounded tirzepatide |
|---|---|---|
| Manufacturer | Eli Lilly | 503A or 503B pharmacy |
| FDA approval | Yes (Nov 2023) | No — compounded products are not FDA-approved |
| Formulation | Pre-filled pen or vial, single-dose | Multi-dose vial, often reconstituted by patient |
| Available strengths | 2.5 / 5 / 7.5 / 10 / 12.5 / 15 mg | Variable (common: 5, 10, 15, 30, 60 mg vials) |
| Concentration consistency | Validated to pharmacopeia standards | Variable across pharmacies and lots |
| Added ingredients | None beyond excipients | Sometimes B12 or lipotropic blends |
| Monthly cost (list) | ~$1,000–$1,100 | ~$300–$500 during shortage |
| Legal status (2026) | Fully approved | Restricted; large-scale 503B compounding largely halted |
| Trial data | SURMOUNT-1 through SURMOUNT-5 | No RCT data on compounded formulations |
| Insurance coverage | Expanding, often with prior auth | Rarely covered |
Regulatory timeline — how we got here
| Date | Event | Impact on compounding |
|---|---|---|
| May 2022 | Mounjaro (tirzepatide for T2D) FDA-approved | Compounding not yet an issue |
| Oct 2022 | FDA declares tirzepatide shortage | 503A and 503B compounding of tirzepatide permitted |
| Nov 2023 | Zepbound (tirzepatide for obesity) FDA-approved | Demand further exceeds supply |
| Oct 2024 | FDA declares shortage resolved | 503B bulk compounding of tirzepatide restricted |
| Late 2024 | Compounder lawsuits and injunctions | Short-term uncertainty, mixed court outcomes |
| 2025 | FDA finalises enforcement; most 503B exits | Large-scale compounded supply dries up |
| 2026 | Narrow 503A patient-specific compounding only | Access and legality highly variable by state |
Why price was the main driver
At the height of the shortage, telehealth clinics were offering compounded tirzepatide monthly subscriptions at $249–$499, versus a Zepbound list price north of $1,000. For patients paying cash — most of them, since insurance coverage of weight-loss medications is still inconsistent — the difference was decisive. By 2026, Lilly's LillyDirect self-pay offering has narrowed the gap substantially, especially for lower doses, but Zepbound remains the more expensive option in most cash-pay comparisons.
Formulation differences that matter
Three real differences distinguish compounded tirzepatide from Zepbound and could affect either efficacy or safety:
- Concentration variability. Zepbound pens are validated to tight limits. Compounded vials rely on the pharmacy's quality system, which varies substantially from one facility to another.
- Added ingredients. B12 is likely harmless but not studied in combination. Lipotropic blends have no evidence base for weight loss on top of tirzepatide and have been criticised by regulators.
- Delivery format. Multi-dose vials require sterile technique and accurate reconstitution math. Zepbound pens remove that risk entirely.
Quality control — the 503A vs 503B distinction
Both compounding pathways are legal in principle but operate under different quality standards:
- 503A traditional pharmacies compound in response to an individual prescription. They are state-regulated, follow USP 797/USP 795 compounding standards, but are not inspected to CGMP manufacturing standards.
- 503B outsourcing facilities can produce in bulk without patient-specific prescriptions. They must register with FDA and comply with CGMP, which is a much higher quality bar — closer to a pharmaceutical manufacturer than a pharmacy.
During the shortage, both pathways were used, but the bulk of the volume moved through 503B. Loss of the 503B pathway in 2024–2025 collapsed the compounded supply chain.
What the 2026 landscape looks like
By late 2026, the practical reality is:
- Large-scale compounded tirzepatide from 503B facilities is no longer legally available.
- Narrow 503A compounding may still occur for patients with documented clinical reasons for a non-standard formulation (for example a true excipient allergy), but it is not a general access pathway.
- Zepbound (and Mounjaro, off-label) is the standard access route, with LillyDirect vials offering a lower-cost option for cash-pay patients.
- "Research-grade" tirzepatide sold without clinical oversight is not a legal or safe substitute for either compounded or approved product.
Access patterns if you were on compounded in 2024
Patients who started weight loss on compounded tirzepatide during the shortage window are a large population now navigating a changed landscape. Three transition patterns have been common:
- Direct switch to Zepbound at the equivalent weekly dose, usually with no washout required because tirzepatide pharmacokinetics are the same across formulations. The main friction is cost and prior authorisation.
- Switch to LillyDirect self-pay vials which, as of 2025–2026, provide 2.5 mg and 5 mg at substantially lower cash prices than the pen format, closing much of the historical price gap.
- Taper or discontinuation for patients unable or unwilling to pay branded prices. Weight regain is common and often rapid in the first 6–12 months after stopping.
None of these transitions require tapering tirzepatide dose by dose — the drug does not have a withdrawal syndrome in the pharmacological sense — but the appetite rebound after stopping is real and well-documented in trial extension data.
Safety signals worth flagging
FDA has publicly flagged several concerns with compounded GLP-1 and dual-agonist products: dosing errors from patient reconstitution and withdrawal, use of unapproved salt forms of the active ingredient (such as tirzepatide "sodium" or "acetate" that are not the FDA-approved tirzepatide molecule), and products marketed with unverified additive ingredients. These signals are not evidence that all compounded tirzepatide was unsafe, but they are reminders that quality assurance in the compounded market was uneven even at the peak of the shortage.
Patients who used compounded product during the shortage and had good outcomes often had good outcomes. Patients who used compounded product and had poor outcomes often never knew whether the issue was dose, formulation, or something else. The absence of a controlled trial on any specific compounded formulation means neither inference is secure.
Insurance and prior authorisation reality
One reason the compounded market grew so large so fast is that commercial insurance coverage of weight-loss medications remains inconsistent. Many plans continue to exclude obesity drugs from the formulary entirely, cover them only for patients with specific BMI and comorbidity thresholds, or require 6 months of documented lifestyle intervention first. Medicare continues to exclude weight-loss drugs under current law, with policy changes repeatedly debated but not yet enacted at scale.
The practical consequence is that a large share of US tirzepatide users are cash-pay. That makes the Zepbound-versus-compounded price comparison not an abstract one but the deciding factor in whether a patient starts, continues, or stops the medication. LillyDirect vial pricing has shifted the arithmetic significantly for lower doses, but at the 10 mg and 15 mg maintenance doses the monthly cash cost remains high enough to be a real barrier.
Conclusion
The compounded-vs-Zepbound debate was really a debate about access during a specific regulatory window. During the shortage, compounded tirzepatide filled a genuine access gap at a much lower price, with real but variable quality trade-offs. After the shortage resolution, the legal basis for large-scale compounding largely disappeared, and by 2026 Zepbound — including its lower-cost LillyDirect vial format — is the practical route for most patients.
If you are starting now, the honest comparison is less "compounded vs branded" than "FDA-approved vs an unregulated grey market." The clinical trial data all exists on branded tirzepatide. The cost gap has narrowed. The quality-control gap has not.
Frequently Asked Questions
Is compounded tirzepatide the same molecule as Zepbound?
Compounded tirzepatide is intended to be the same molecule, but it is not FDA-approved, concentration consistency varies by pharmacy, and some compounded formulations include additional ingredients like B12 or lipotropic blends that are not part of Zepbound.
Why is compounded tirzepatide cheaper?
Compounded pharmacies do not carry the research, development, and brand costs of a pharmaceutical manufacturer, and during the shortage they could produce at scale. By 2026, Lilly's LillyDirect self-pay program has substantially narrowed the price gap.
Is compounded tirzepatide still legal in 2026?
Large-scale 503B compounding of tirzepatide is restricted following the October 2024 shortage resolution. Narrow 503A patient-specific compounding may still occur under limited circumstances, but access is far more limited than during the 2022–2024 shortage.
Can I switch from compounded tirzepatide to Zepbound?
Yes, and in many 2026 scenarios this is the available path. A prescriber will typically match the equivalent weekly dose and continue titration. Insurance coverage and prior authorisation vary.
Did compounded tirzepatide work as well as Zepbound?
There is no randomised trial data comparing them directly. Anecdotally, many patients lost weight on compounded tirzepatide at expected rates, but concentration variability and added ingredients make outcomes less predictable than with the approved product.
What about tirzepatide sold as "research chemical" or "not for human use"?
Products sold under research-chemical labels are not legally supplied for human administration, carry no quality guarantees, and may contain anything from accurately dosed tirzepatide to degraded peptide to the wrong molecule entirely. They are outside both the compounded and approved frameworks.
Sources
- FDA. Policies for compounders in national drug shortages. fda.gov tirzepatide compounding policy
- FDA Zepbound (tirzepatide) prescribing information. 2023. accessdata.fda.gov Zepbound label
- Jastreboff AM et al. SURMOUNT-1. NEJM. 2022. nejm.org/doi/full/10.1056/NEJMoa2206038
- FDA. Human drug compounding — 503A and 503B. fda.gov/drugs/human-drug-compounding
- PubMed. Tirzepatide clinical trial literature. pubmed.ncbi.nlm.nih.gov/?term=tirzepatide
Research disclaimer: This article is written by the Peptides Hive Research Desk and summarises public regulatory and clinical data for educational purposes only. It is not medical, legal, or regulatory advice. Compounded medication rules change frequently and vary by state; verify current status with a licensed pharmacist or your state board of pharmacy before any treatment decision.
